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Objectives: To estimate the cost-effectiveness of nab-paclitaxel+gemcitabine (Npg) 
versus gemcitabine (Gem) alone for the first-line treatment of metastatic pancreatic 
cancer in Greece from a National Health System perspective MethOds: A Markov 
model was developed, included several stages such as: “pre-progression on first-
line treatment”, “pre-progression off first-line treatment”, “post progression”, “four 
weeks to death” and “death”. Data from the MPACT trial were used to estimate overall 
survival (Life-Years- (LYs)) and adverse events. The prices of drugs used in the model 
are publicly available for all hospitals in Greece. Cost assigned in each health state 
reflected: drugs, adverse events, monitoring, administration and palliative care. Utility 
values were obtained from the international literature to estimate Quality-Adjusted-
Life-Years (QALYs). Costs and health gains were discounted at 3.5% per annum. A 
probabilistic sensitivity analysis was also conducted to construct confidence inter-
vals (CI). Results: The mean number of QALYs was 0.71 (95%CI: 0.66–0.78) and 0.56 
(95%CI: 0.52–0.60) for Npg and Gem, respectively, giving an incremental gain of 0.15 
(95%CI: 0.08-0.25) QALYs in favour of Npg. The mean cost of therapy per patient was 
estimated at € 15,628 (95%CI: € 14,377- € 17,027) and € 8,284 (95%CI: € 7,455-€ 9,112) for 
Npg and Gem, respectively. The incremental cost per LY gained with Npg was esti-
mated at € 37,007 and the incremental cost per QALY gained at € 47,120. The probability 
for Npg to be cost-effective at a threshold three times the per capita income (€ 60,000 
per QALY) was 82%. cOnclusiOns: The severity of pancreatic cancer, in combination 
with the limited number of effective treatments, results in a high level of unmet need. 
If the societal willingness-to-pay threshold for an additional QALY is relatively higher 
for patients with short life expectancy or for diseases with a relatively higher burden, 
the combination of nab-paclitaxel+gemcitabine could be considered a cost-effective 
choice compared with gemcitabine alone in Greece.
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Objectives: To compare the cost-effectiveness of panitumumab plus mFOLFOX6 
(oxaliplatin, 5-fluorouracil and leucovorin) versus bevacizumab plus mFOLFOX6 
as first-line treatment for patients with wild-type RASmetastatic colorectal cancer 
(mCRC). MethOds: Using a French health collective perspective, a lifetime Markov 
model was constructed, with health states related to first-line therapy (progression-
free), disease progression with/without subsequent active treatment, resection of 
metastases, disease-free after successful resection, and death. Transitions to disease 
progression and death were estimated using parametric survival analyses of patient-
level progression-free (PFS) and overall (OS) survival from the only head-to-head clini-
cal trial of panitumumab versus bevacizumab in mCRC (PEAK). Additional data from 
PEAK informed the amount of each drug consumed, duration of therapy, subsequent 
therapy use, and toxicities related to mCRC treatment. Literature and French public 
data sources were used to estimate unit costs associated with treatment, duration 
of subsequent active therapies, and survival post-resection. Patient-level data from 
panitumumab trials in the first-, second-, and third-line settings were used to deter-
mine utility weights. One-way and probabilistic sensitivity analyses were performed. 
Scenario analyses examined modelling of PFS and OS using observational survival 
data and PEAK hazard ratios. Results: Based on the better efficacy outcomes for 
patients with wild-type RASmCRC who received panitumumab plus mFOLFOX6 ver-
sus bevacizumab plus mFOLFOX6 in PEAK, the incremental cost per life-year gained 
was estimated to be € 26,918, and the incremental cost per quality-adjusted life year 
(QALY) gained was estimated to be € 36,577. Sensitivity and scenario analyses indi-
cate the model is robust to alternative parameters and assumptions. cOnclusiOns: 
Panitumumab plus mFOLFOX6 can be considered cost-effective in first-line treatment 
of patients with wild-type RAS mCRC.
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Objectives: To assess the cost-utility of pazopanib vs. sunitinib as first-line treat-
ment of mRCC from the Spanish National Healthcare perspective. MethOds: A 
published partitioned-survival analysis model was used to estimate the incremental 
cost-utility ratio (ICUR) of pazopanib vs. sunitinib. Progression free survival (PFS) and 
overall survival (OS) data from COMPARZ (NCT00720941), a non-inferiority head to 
head phase III-trial of sunitinib vs. pazopanib, were used to generate survival func-
tions up to overall time horizon. Patients can be in one of three mutually exclusive 
health states over time: alive and no progression, alive with progression and dead. 
Utilities values were obtained from PISCES trial (NCT01064310) and adjusted tak-
ing into account the different treatment schedules (sunitinib-cycles: 4 weeks-on 
plus2 weeks-off; pazopanib 800 mg/day). Health resource utilization was collected 
using individual patient data from COMPARZ trial and their corresponding unit 
costs were retrieved from published Spanish tariffs. Base-case analysis considered: 
ing to develop a targeted contrast agent that specifically detects adenomas at 
increased risk of progressing to CRC. This might even further raise the potential 
of MR colonography. We explored the potential of conventional and targeted MR 
colonography in terms of (cost-) effectiveness using the ASCCA model. MethOds: 
Thirteen screening strategies were evaluated, differing in primary screening 
instrument and number of screening rounds. The strategies under consideration 
were conventional and targeted MR colonography, colonoscopy and CT colonog-
raphy with two, three and four screening rounds at a ten year screening interval. 
Furthermore, eleven rounds of biennial faecal immunochemical test (FIT) screen-
ing were considered. Each strategy was evaluated assuming realistic and perfect 
participation rates. Incremental costs and effects were estimated from a societal 
perspective. Results: All screening strategies were cost-effective compared to 
no screening. For conventional MR colonography, the ICER ranged between € 1,271/
LYG to € 3,003/LYG for two to four screening rounds at 34% participation per round. 
For 62% and 100% participation, the ICER ranged from respectively € 1,576/LYG to 
€ 3,777/LYG and € 1,971/LYG to € 4,577/LYG. However, conventional MR colonography 
screening was more expensive than other screening strategies at comparable 
LYG, for all participation rates. Targeted MR colonography was only slightly more 
effective than conventional MR colonography but considerably more costly, even 
under the most favourable assumptions regarding test characteristics and costs 
per test. cOnclusiOns: This is the first study to evaluate the cost-effectiveness 
of MR colonography screening for CRC. Although conventional and targeted MR 
colonography are cost-effective compared to no screening, at present they cannot 
compete with more established screening tests because of the high costs per test.
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Objectives: To assess the cost-effectiveness of Abiraterone Acetate plus 
Prednisone (A-P) compared with Cabazitaxel plus Prednisone (C-P) in Panama, 
in patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) that 
have failed to chemotherapy with Docetaxel. MethOds: A three-health state 
cohort simulation Markov Model (progression-free, post-progression and death) 
was developed based on overall and progression free survival data. The time frame 
was 10 years. The perspective was that of the Public System of Health of Panama. 
The health outcomes of interest were Quality Adjusted Life Years (QALYs) and Life 
Years (LYs). Efficacy data was taken from clinical trials (COU-AA-301 for A-P and 
TROPIC for C-P). Utilities for health states and negative utilities for adverse events 
were estimated based on quality of life endpoints of the COU-AA-301 trial. The 
base year was 2012. All costs are presented in United States Dollars (USD). Costs 
and outcomes were discounted at 5%. Probabilistic sensitivity (PSA) analysis was 
performed to evaluate uncertainty surrounding the parameters. Results: A-P 
resulted in 0.79 QALYs and 1.35 LYs, per patient, respectively. C-P resulted in 0.71 
QALYs and 1.28 LYs, per patient, respectively. Mean total costs per patient were: 
USD 76.179 for A-P and USD 86.286 for C-P. The results of the probabilistic sensitiv-
ity analysis showed that, when compared with C-Z, A-P was found dominant (asso-
ciated with reduced costs and increased QALYs) in the majority of the iterations. 
A-P had a 73% probability of being cost effective, independent of the willingness 
to pay, when compared to C-P. When the willingness to pay increases, A-P is more 
likely to become cost effective. cOnclusiOns: A-P can be considered dominant 
(cost-saving), when compared with C-P, in patients with Metastatic Castration-
Resistant Prostate Cancer that have failed to chemotherapy with Docetaxel, from 
the perspective of the Public System of Health of Panama.
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Objectives: This study evaluated the cost-effectiveness of everolimus plus exemes-
tane (EVE+EXE) versus exemestane (EXE) and fulvestrant (FUL) in the treatment of 
postmenopausal women with ER+ HER2- metastatic breast cancer in the United 
Kingdom (UK) from a societal perspective. MethOds: A partitioned survival model 
was developed to compare treatment with EVE+EXE versus EXE and FUL over a 
10-year time horizon. Progression-free survival and overall survival for EVE+EXE 
and EXE were estimated from the BOLERO-2 trial. Log-logistics functions were used 
to extrapolate trial data beyond the follow-up period. In the absence of head-to-
head evidence vs. FUL an indirect treatment comparison was conducted using a 
Bayesian fixed effect model. Background health state and terminal care resource 
use were derived from NICE Clinical Guideline 81. Drug costs were taken from the 
British National Formulary. Productivity loss, defined as working days lost due to 
disease, was included in the analysis. Utilities from published sources were com-
bined with trial data to calculate quality-adjusted life years (QALYs) for the model 
health state. Results: EVE+EXE led to an incremental gain in life years of 0.20 vs. 
EXE and 0.19 vs. FUL. The incremental QALY gain was 0.31 vs. EXE and 0.27 vs. FUL. 
The cost of lost productivity was £66,163 in the EVE+EXE compared to £75,067 in the 
EXE arm and £73,434 in the FUL arm. The incremental cost per QALY was £27,644 
vs. EXE and £14,030 vs. FUL. Probabilistic sensitivity analysis demonstrated that, at 
a threshold of £30,000 per QALY gained, EVE+EXE had a 51.6% likelihood of being 
cost-effective vs. EXE and 59.0% vs. FUL. cOnclusiOns: Patients receiving EVE+EXE 
experienced an improvement in survival which translated into health gains in terms 
of both LYs and QALYs. EVE+EXE was associated with savings in productivity costs 
compared to both EXE and FUL.
